Article | August 18, 2021

Building An Army: Cell Therapy Platforms With Dr. Helen Sabzevari, CEO Of Precigen

Source: Cytiva

By Cytiva


Two of the greatest challenges in cell therapy development and driving new therapies toward commercial success are scalability and optimizing cost.

As the CEO of Precigen, a biopharmaceutical company dedicated to pursuing solutions for a range of intractable diseases through early discovery and clinical-stage research, Dr. Helen Sabzevari is ready to face these challenges. Dr. Sabzevari has spent years considering what it takes for rapid drug development and commercial viability in today’s market. Her previous work includes tenures in both academia and with EMD Serono, Compass Therapeutics, and Intrexon (now Precigen).

In a recent episode of The Business of Biotech, Dr. Sabzevari discussed how Precigen has used customized therapeutic and platform technologies to tackle scale-up in the CAR-T therapeutics space, helping patients and investors know they’re getting the most effective therapy at the best price.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development